Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

NCT03704298 ·Status: TERMINATED ·Phase: PHASE1

Axi-cel Retreatment in Relapsed/Refractory LBCL

NCT05800067 ·Status: UNKNOWN ·Phase: NA

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

NCT06079164 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

NCT03761056 ·Status: COMPLETED ·Phase: PHASE2

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466 ·Status: COMPLETED ·Phase: PHASE3

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NCT06935136 ·Status: NOT_YET_RECRUITING ·Phase: NA

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

NCT05590221 ·Status: RECRUITING ·Phase: PHASE2

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

NCT02840110 ·Status: TERMINATED

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

NCT03736616 ·Status: UNKNOWN ·Phase: PHASE2

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

NCT07254754 ·Status: RECRUITING ·Phase: PHASE2

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

NCT05788081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

NCT04855253 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

NCT05658562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Frontline of ASCT in High-risk DLBCL

NCT05831865 ·Status: RECRUITING

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526 ·Status: COMPLETED ·Phase: PHASE1

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

NCT04257578 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Combination Study of CAR-T Therapy in r/r B-NHL

NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267 ·Status: COMPLETED ·Phase: PHASE1

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

NCT00880581 ·Status: COMPLETED ·Phase: PHASE2

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

NCT06760156 ·Status: RECRUITING ·Phase: PHASE2

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

NCT00829205 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Odronextamab in Low Tumor Volume Advanced FL

NCT07128641 ·Status: RECRUITING ·Phase: PHASE2